Compare GKOS & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | ASLE |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | 1094 | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 296.8M |
| IPO Year | 2015 | 2018 |
| Metric | GKOS | ASLE |
|---|---|---|
| Price | $103.21 | $6.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 2 |
| Target Price | ★ $133.07 | $7.00 |
| AVG Volume (30 Days) | ★ 634.7K | 254.9K |
| Earning Date | 04-29-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.64 |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $507,442,000.00 | $335,286,000.00 |
| Revenue This Year | $23.39 | $24.23 |
| Revenue Next Year | $27.46 | $23.67 |
| P/E Ratio | ★ N/A | $35.08 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $5.56 |
| 52 Week High | $130.23 | $9.08 |
| Indicator | GKOS | ASLE |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 27.72 |
| Support Level | $81.54 | $5.69 |
| Resistance Level | $113.50 | $6.56 |
| Average True Range (ATR) | 3.93 | 0.24 |
| MACD | -0.78 | -0.08 |
| Stochastic Oscillator | 31.42 | 9.57 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.